Myeloid growth factors, version 2.2017: Clinical practice guidelines in oncology Journal Article
| Authors: | Crawford, J.; Becker, P. S.; Armitage, J. O.; Blayney, D. W.; Chavez, J.; Curtin, P.; Dinner, S.; Fynan, T.; Gojo, I.; Griffiths, E. A.; Hough, S.; Kloth, D. D.; Kuter, D. J.; Lyman, G. H.; Mably, M.; Mukherjee, S.; Patel, S.; Perez, L. E.; Poust, A.; Rampal, R.; Roy, V.; Rugo, H. S.; Saad, A. A.; Schwartzberg, L. S.; Shayani, S.; Talbott, M.; Vadhan-Raj, S.; Vasu, S.; Wadleigh, M.; Westervelt, P.; Burns, J. L.; Pluchino, L. |
| Article Title: | Myeloid growth factors, version 2.2017: Clinical practice guidelines in oncology |
| Abstract: | Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimenand patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice. © JNCCN-Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 12 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-12-01 |
| Start Page: | 1520 |
| End Page: | 1541 |
| Language: | English |
| DOI: | 10.6004/jnccn.2017.0175 |
| PROVIDER: | scopus |
| PUBMED: | 29223990 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 January 2018 -- Source: Scopus |
